Literature DB >> 11701730

IGF type 1 receptor ligand binding characteristics are altered in a subgroup of children with intrauterine growth retardation.

B Ducos1, S Cabrol, M Houang, L Perin, M Holzenberger, Y Le Bouc.   

Abstract

The IGFs, IGF-I and IGF-II, regulate fetal growth by activating IGF type 1 receptors (IGF-IR). We aimed to quantify the binding of IGF-I to its cognate receptors in intrauterine growth-retarded children (IUGR). We measured the affinity of the erythrocyte IGF-IR and the number of IGF-IR receptors in 17 children with retarded growth (mean height, -2.7 SD), normal levels of GH, and a history of idiopathic intrauterine growth retardation (height at birth, -10 to -2 SD; mean, -3.1 SD). These children had reduced receptor affinity (Kd = 0.47 nM; P < 0.01) and more receptors per cell [binding capacity (Bmax) = 11.7 binding sites/cell; P < 0.05)] compared with control children (Kd = 0.32 nM; Bmax = 7.8 binding sites/cell). Moreover, the distributions of Kd and Bmax suggested that there were two groups of IUGR children. Group 1 included subjects with normal receptor binding function (Kd = 0.36 nM; Bmax = 8.2 sites/cell) and normal levels of circulating IGF-I. Group 2 comprised children with low receptor affinity (Kd = 0.56 nM) and increased receptor number (Bmax = 14.7 sites/cell). This group showed significantly decreased IGF-I levels (-2.1 SD; P < 0.01). We investigated these IGF-IR binding parameters in two additional groups of growth-retarded children (Turner syndrome and patients with chronic renal failure), in whom the IGF-I axis was not believed to be the primary cause, and found that Kd and Bmax were normal or nearly normal. We also measured IGF-IR binding parameters in 4 Seckel syndrome patients with IUGR and severely retarded growth (mean height, -7.9 SD). Their receptor affinity was reduced, but not statistically different, from that in controls, and their receptor number was normal, whereas IGF-I levels were elevated. Our results suggest heterogeneous alterations in IGF-IR binding function in IUGR patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701730     DOI: 10.1210/jcem.86.11.7985

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Clinical examples of disturbed IGF signaling: intrauterine and postnatal growth retardation due to mutations of the insulin-like growth factor I receptor (IGF-IR) gene.

Authors:  W Kiess; J Kratzsch; E Keller; A Schneider; K Raile; J Klammt; B Seidel; A Garten; H Schmidt; R Pfäffle
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

2.  High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer.

Authors:  Aziz Zaanan; Claire Calmel; Julie Henriques; Magali Svrcek; Hélène Blons; Christèle Desbois-Mouthon; Fatiha Merabtene; Claire Goumard; Yann Parc; Brice Gayet; Julien Taieb; Pierre Validire; Christophe Louvet; Jean-François Fléjou; Yves Le Bouc; Françoise Praz
Journal:  Cell Oncol (Dordr)       Date:  2019-12-10       Impact factor: 6.730

3.  Clinical and functional characterization of a patient carrying a compound heterozygous pericentrin mutation and a heterozygous IGF1 receptor mutation.

Authors:  Eva Müller; Desiree Dunstheimer; Jürgen Klammt; Daniela Friebe; Wieland Kiess; Jürgen Kratzsch; Tassilo Kruis; Sandy Laue; Roland Pfäffle; Tillmann Wallborn; Peter H Heidemann
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.